Faz 1/2 Jijman mete nan tès ASC618, Terapi jèn pou emofili A

Faz 1/2 Jijman mete nan tès ASC618, Terapi jèn pou emofili A

Emofili Nouvèl Jodi a

Imaj

Please enable the javascript to submit this form

Sipòte pa sibvansyon edikasyon bay Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, ak uniQure, Inc.

Esansyèl SSL